BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18751980)

  • 1. [Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma].
    Luu VD; Fischer B; von Teichman A; Boysen G; Mertz K; Zimmermann P; Moch H; Schraml P
    Pathologe; 2008 Nov; 29 Suppl 2():303-7. PubMed ID: 18751980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
    Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
    Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
    Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
    Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
    Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
    J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
    Beroukhim R; Brunet JP; Di Napoli A; Mertz KD; Seeley A; Pires MM; Linhart D; Worrell RA; Moch H; Rubin MA; Sellers WR; Meyerson M; Linehan WM; Kaelin WG; Signoretti S
    Cancer Res; 2009 Jun; 69(11):4674-81. PubMed ID: 19470766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VHL gene alterations in Italian patients with isolated renal cell carcinomas.
    Muscarella LA; D'Agruma L; la Torre A; Gigante M; Coco M; Parrella P; Battaglia M; Carrieri G; Carella M; Zelante L; Fazio VM; Gesualdo L; Ranieri E
    Int J Biol Markers; 2013 Jun; 28(2):208-15. PubMed ID: 23558940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
    Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
    Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of biallelic inactivation of the von Hippel-Lindau tumor suppressor gene VHL in patients of renal cell carcinoma patient].
    Liu N; Gong K; Zhang N; Guo HF; Na X; Wu G; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(2):115-7. PubMed ID: 15771820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
    Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
    Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
    Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
    Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.